Posts by: Alice Melão

The European Union has approved Pfizer‘s Besponsa as a treatment for adults with a type of B-cell leukemia. The authorization applies to patients with relapsed or refractory CD22-positive B-cell acute ... Read more

July 5, 2017

FDA Approves New Diagnostic Tool for Leukemias and Lymphomas

News

The U.S. Food and Drug Administration (FDA) has approved a new laboratory test to help clinicians detect leukemia and lymphoma cells using a technique called flow cytometry. The ClearLLab ... Read more

June 29, 2017June 29, 2017

Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. ... Read more

June 26, 2017June 26, 2017

ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL

News

Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and ... Read more

June 23, 2017June 23, 2017

Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial

News

Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental ... Read more

June 2, 2017June 2, 2017

Potential Treatment for a Number of Blood Cancers, ASN002, Enters Phase 2 Trial

News

Following positive results in a dose–escalation trial with non-Hodgkin’s lymphoma (NHL) patients, a Phase 2 trial will now evaluate a new kinase inhibitor, ASN002, in the treatment of several ... Read more

May 10, 2017May 10, 2017

Chest Radiation Therapy Increases Risk of Severe Coronary Artery Disease in Hodgkin Lymphoma Patients

News

A Dutch study found that Hodgkin lymphoma survivors who received chest irradiation are more likely to develop severe coronary artery disease (CAD) 20 years after treatment than those without Hodgkin lymphoma ... Read more

May 5, 2017May 5, 2017

Mallinckrodt Marks 30 Years of Treating Skin Problems in CTCL Patients Using ECP

News

Extracorporeal photopheresis (ECP) therapy for palliative care of skin manifestations of cutaneous T-cell lymphoma (CTCL) was approved 30 years ago and remains an important therapeutic tool worldwide. Mallinckrodt, the ... Read more